← All Kalvista Pharmaceuticals, INC filings

Kalvista Pharmaceuticals, INC Form 4 insider transactions

NASDAQ
KALV
Kalvista Pharmaceuticals, INC
Form 4: KalVista Pharmaceuticals Director William Fairey Acquires 17,000 Stock Options
Director William Fairey acquired 17,000 stock options in KalVista Pharmaceuticals on April 18, 2024.
NASDAQ
KALV
Kalvista Pharmaceuticals, INC
Form 4: KalVista Pharmaceuticals CEO Benjamin L. Palleiko Reports Acquisition of 250,000 Restricted Stock Units
Benjamin L. Palleiko, CEO of KalVista Pharmaceuticals, reported the acquisition of 250,000 restricted stock units (RSUs) on March 6, 2024, according to a Form 4 filing with the SEC.